Literature DB >> 22575430

Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia.

Shih-Tse Huang1, Mei-Chun Chiang, Shu-Chen Kuo, Yi-Tzu Lee, Tong-Hong Chiang, Su-Pen Yang, Te-Li Chen, Chang-Phone Fung.   

Abstract

BACKGROUND: It is still controversial whether carbapenem-resistant Acinetobacter baumannii (CRAB) is an independent risk factor for mortality. This study aimed to determine the risk factors and outcomes of patients with CRAB bacteremia, compared to those with carbapenem-susceptible A. baumannii (CSAB) bacteremia.
METHODS: This retrospective cohort study was conducted in Taipei Veterans General Hospital, Taiwan. Patients with bacteremia due to A. baumannii during June 2002 and December 2007 were included.
RESULTS: A total of 62 patients with CRAB and 164 with CSAB bacteremia were included. Among these patients, the independent risk factors for acquiring CRAB bacteremia were hematological malignancy [odds ratio (OR): 4.04; 95% confidence interval (CI): 1.29-12.70; p = 0.017], previous use of cefepime (OR: 2.60; 95% CI 1.11-6.08; p = 0.028) and use of total parenteral nutrition (OR: 3.06; 95% CI 1.12-8.39; p = 0.029). The patients with CRAB bacteremia had higher mortality rate than those with CSAB bacteremia. However, multivariate analysis showed that among patients with A. baumannii bacteremia, acquisition of CRAB by itself was not an independent risk factor for 14-day mortality. Instead, the independent factors predicting14-day mortality were Acute Physiology and Chronic Health Evaluation (APACHE) score > 20 (OR: 6.33; 95% CI: 2.32-17.26; p < 0.001), shock (OR: 2.68; 95% CI: 1.11-6.23; p = 0.025) and inappropriate antimicrobial therapy (OR: 2.14; 95% CI: 1.01-4.53; p = 0.046).
CONCLUSION: Risk factors for CRAB bacteremia were hematological malignancies, previous use of cefepime and use of total parenteral nutrition. Acquisition of CRAB itself is not a poor prognostic factor for the patients with A. baumannii bacteremia.
Copyright © 2012. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22575430     DOI: 10.1016/j.jmii.2011.12.009

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  24 in total

1.  Identification, genotypic relation, and clinical features of colistin-resistant isolates of Acinetobacter genomic species 13BJ/14TU from bloodstreams of patients in a university hospital.

Authors:  Seung Yeob Lee; Jong Hee Shin; Kyung Hwa Park; Ju Hee Kim; Myung Geun Shin; Soon Pal Suh; Dong Wook Ryang; Soo Hyun Kim
Journal:  J Clin Microbiol       Date:  2014-01-08       Impact factor: 5.948

2.  Risk factors and clinical outcomes for intensive care unit patients with mul-tidrug-resistant Acinetobacter spp. bacteremia.

Authors:  Malbaša Đekić; T Dugandžija; G Dragovac; D Medić; M Paut Kusturica
Journal:  Hippokratia       Date:  2020 Jan-Mar       Impact factor: 0.471

3.  Acinetobacter baumannii bacteraemia in patients with haematological malignancy: a multicentre retrospective study from the Infection Working Party of Jiangsu Society of Hematology.

Authors:  X Wang; L Zhang; A Sun; X Yang; W Sang; Y Jiang; J Cheng; J Wang; M Zhou; B Chen; J Ouyang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-01-18       Impact factor: 3.267

4.  Minocycline Alone and in Combination with Polymyxin B, Meropenem, and Sulbactam against Carbapenem-Susceptible and -Resistant Acinetobacter baumannii in an In Vitro Pharmacodynamic Model.

Authors:  Maya Beganovic; Kathryn E Daffinee; Megan K Luther; Kerry L LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

Review 5.  Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside.

Authors:  Ming-Feng Lin; Chung-Yu Lan
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

6.  Risk factors and outcomes for patients with bloodstream infection due to Acinetobacter baumannii-calcoaceticus complex.

Authors:  Teena Chopra; Dror Marchaim; Paul C Johnson; Reda A Awali; Hardik Doshi; Indu Chalana; Naomi Davis; Jing J Zhao; Jason M Pogue; Sapna Parmar; Keith S Kaye
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191

7.  Clinical and Epidemiological Significance of Carbapenem Resistance in Acinetobacter baumannii Infections.

Authors:  Ruthy Tal-Jasper; David E Katz; Nadav Amrami; Dor Ravid; Dori Avivi; Ronit Zaidenstein; Tsilia Lazarovitch; Mor Dadon; Keith S Kaye; Dror Marchaim
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

8.  The deadly impact of extreme drug resistance in Acinetobacter baumannii.

Authors:  Brad Spellberg; Robert A Bonomo
Journal:  Crit Care Med       Date:  2014-05       Impact factor: 7.598

9.  Clinical outcomes of hospital-acquired infection with Acinetobacter nosocomialis and Acinetobacter pittii.

Authors:  Sarunyou Chusri; Virasakdi Chongsuvivatwong; Jesabel I Rivera; Kachornsakdi Silpapojakul; Kamonnut Singkhamanan; Edward McNeil; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2014-05-12       Impact factor: 5.191

10.  Comparative Phosphoproteomics Reveals the Role of AmpC β-lactamase Phosphorylation in the Clinical Imipenem-resistant Strain Acinetobacter baumannii SK17.

Authors:  Juo-Hsin Lai; Jhih-Tian Yang; Jeffy Chern; Te-Li Chen; Wan-Ling Wu; Jiahn-Haur Liao; Shih-Feng Tsai; Suh-Yuen Liang; Chi-Chi Chou; Shih-Hsiung Wu
Journal:  Mol Cell Proteomics       Date:  2015-10-23       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.